CA2345722A1 — Determining resistance to treatment for hepatitis c virus
Assigned to Diacrin Inc · Expires 2000-04-06 · 26y expired
What this patent protects
Methods for identifying hepatitis C virus (HCV)-infected subjects responsive to treatment for HCV infection or unlikely to respond to treatment for HCV infection are described. The level of Th2 cytokines in the subject during treatment serves as an indicator of whether the subje…
USPTO Abstract
Methods for identifying hepatitis C virus (HCV)-infected subjects responsive to treatment for HCV infection or unlikely to respond to treatment for HCV infection are described. The level of Th2 cytokines in the subject during treatment serves as an indicator of whether the subject is likely to respond to treatment for HCV, e.g., interferon treatment. An elevated level of at least one Th2 cytokine during treatment indicates that an HCV-infected subje ct is unlikely to respond to a treatment for HCV. A decreased level of at least one TH2 cytokine indicates that an HCV-infected subject is responsive to a treatment for HCV. In a preferred embodiment, IL-10 levels are detected to identify subjects responsive to or unlikely to respond to interferon treatme nt.
Drugs covered by this patent
- Imbruvica (ibrutinib) · AbbVie
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.